Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ECRI Personalized Medicine Conference
CER and Personalized Medicine Face Hurdles
By
Colin Gittens
ECRI Personalized Medicine Conference
November/December 2010, Vol 1, No 6
Bethesda, MD—Implementing and effectively using comparative effectiveness research (CER) and personalized medicine (PM) will require time and better communication among the research community conducting these types of studies and with the public that will be impacted by them, according to participants in a panel discussion on the societal implications of CER and PM held during the ECRI Institute’s Comparative Ef fectiveness and Personalized Medicine: An Essential Interface conference.
Read Article
Determining Coverage for CER and Personalized Medicine
By
Colin Gittens
ECRI Personalized Medicine Conference
November/December 2010, Vol 1, No 6
Bethesda, MD—Greater adoption of personalized medicine and comparative effectiveness research (CER) in healthcare will depend on coverage of these approaches by public and private payers. But payer evaluation of these approaches is hampered by legislative roadblocks and a lack of research in CER and slowness in adopting CER into clinical practice, according to speakers at a session of the ECRI Institute’s Comparative Effectiveness and Personalized Medicine: An Essential Interface conference.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma